Commonly used drugs Pansentin API is monopolized by the pharmaceutical companies unprofitable to make a drug hard to find

Commonly used drug "Pansentin" is hard to find, raw materials are monopolized.

Cao Xueping

On the one hand, there is a serious shortage in the market, but on the other hand, there is no one to produce it.

The shortage of Pansentin, a commonly used drug, is getting more and more serious. Pansentin, also known as dipyridamole, is a commonly used drug for preventing thromboembolic diseases, as it dilates coronary blood vessels, promotes the formation of collateral circulation, and has mild anticoagulant and antiviral effects. But now it is difficult to find the drug on the market.

According to information on the website of the State Food and Drug Administration (SFDA), a total of 10 manufacturers have approvals for the production of dipyridamole APIs, and another 216 pharmaceutical companies have approval numbers for dipyridamole tablets. Why is it so difficult to find a commonly used drug that has been approved by 216 pharmaceutical companies?

An investigation by a China Business News reporter found that the low bidding price of the drug made it unprofitable for pharmaceutical companies to give up the production of Pansentin. In addition, the raw materials are gradually concentrated in the hands of a dealer, or artificially exacerbated the supply shortage of dipyridamole API.

Unprofitable

According to industry insiders, there are three main drugs of dipyridamole: dipyridamole injection, dipyridamole extended-release capsules and dipyridamole tablets. It used to be a common drug for the treatment of coronary heart disease in the early years, but is now less used as an antimyocardial ischemia. Its anti-platelet aggregation effect can be used in heart surgery or valve replacement to reduce the formation of thromboembolism.

According to industry sources, Tianjin Lixiang Pharmaceutical Co., Ltd, Shanxi Yabao Pharmaceutical Group Co., Ltd, Shanghai Xinyi Jiufu Pharmaceutical Co.

October 21, Tianjin Lixiang Pharmaceutical Co., Ltd. sales department staff told this reporter, now they do not have goods dipyridamole tablets, mainly because of the shortage of raw materials, it is estimated to next month to resume production and supply.

Shanghai Huashi Pharmacy staff said on the phone, Xinyi Jiufu production of dipyridamole tablets are now out of stock, there were sales, and now all manufacturers are not.

Ltd. staff told this reporter, now the company only only Shanxi Yabao production of dipyridamole tablets supply, no other manufacturers.

October 22, Shanxi Yabao Pharmaceutical Group Co., Ltd. executive deputy general manager Tang Ke frankly admitted in an interview with this reporter, at present, because of increased environmental costs, Yabao Pharmaceuticals production of a kilogram of dipyridamole API costs in one thousand yuan or so, but dipyridamole tablets into the hospital bid price is too low, the company's own production of raw materials for the production of dipyridamole tablets is also a "loss of money too The company uses its own API to produce dipyridamole tablets is also "losing money". "In order not to be included in the bidding department of the drug 'loss of trust' list, can only bite the bullet to ensure that the supply has won the bidding of the region, did not win the bidding of the region basically give up sales."

"The cost of raw materials has risen sharply, but the winning bid price of the drug has not changed for many years, and continued production can only fall into a loss. Dipyridamole tablets manufacturers generally encountered difficulties, have no choice but to give up production." An industry source said.

In fact, not only is pyrimethamine tablets, fish essence protein, Yin Qiao Chong, Vibramycin Lutong these people are familiar with the cheap drug is now also a drug hard to find.

A sample survey on the clinical use of drugs in more than 40 tertiary hospitals in 12 cities across the country shows that there are more than 500 kinds of basic drugs supplemented by the state and the local government, and the shortage has been as high as 342 kinds.

In April 2014, in order to encourage the incentive of pharmaceutical enterprises to produce low-priced drugs and reduce the burden of patients using high-priced drugs, eight ministries and commissions, including the National Health and Planning Commission, issued the "Opinions on Improving the Work of Guaranteeing the Supply of Commonly Used Low-Priced Drugs", which put forward the policy of guaranteeing the production and supply of commonly used low-priced drugs by abolishing the maximum retail price limit for chemical drugs and proprietary Chinese medicines costing up to RMB 3 or 5 per day of service, and allowing pharmaceutical enterprises to independently set or adjust the The maximum retail price limit was abolished, and pharmaceutical enterprises were allowed to set or adjust retail prices on their own to safeguard reasonable profits.

On May 8 of that year, the National Development and Reform Commission (NDRC) officially released the List of Low-Priced Drugs within Pricing, in which Dipyridamole tablets were also included, but the fate of its supply shortage did not change.

So, since the cost is already high and the price has been liberalized, why not raise the price?

A reluctant to disclose the name of the manufacturer's responsible person said, bispyrimethamine tablets are both national essential drugs, but also class A medical insurance drugs. In accordance with China's current national essential drug system, all public medical institutions to use essential drugs must be entered through centralized procurement bidding. The bidding price of drugs is the maximum price of drugs purchased by hospitals, dipyridamole tablets into the hospital is settled at the bidding price, increase the retail price limit on the enterprise is not helpful.

According to the reporter in the online pharmacy search shows, Shiyao Group Ouyi Pharmaceutical Co., Ltd. produced dipyridamole tablets (specifications for 25mg × 100 tablets), the retail price of 18 yuan per bottle. And in the 2013 Sichuan Provincial Drug Purchase Bidding, the company's same specifications